April 1st 2021
The ILLUMINATE-A trial of lumasiran in patients with primary hyperoxaluria type 1 supported the FDA approval of this drug.
September 12th 2012
August 29th 2012
Endoscopic Tx of VUR shows cure rates above 90%
June 1st 2005Atlanta--Children treated with endoscopic intervention for vesicoureteral reflux continue to demonstrate cures that approach those of open surgery and have a high resolution rate after initial failure. In addition, incidence of febrile and non-febrile urinary tract infection after treatment is lower than after surgery, according to data presented here at the State-of-the-Art Symposium on Pediatric UTI, Reflux, Antibiotic Resistance, and Endoscopy.
Study shows genitofemoral grafts feasible during RP
June 1st 2005San Antonio--Genitofemoral (GF) nerve grafting during radical retropubic prostatectomy can be performed safely with a low risk of postoperative morbidity and shows promising efficacy for returning erectile function after surgery involving wide nerve resection, according to the results of a retrospective study.
Legislation would end Medicare/Medicaid funding for ED drugs
May 26th 2005Sen. Chuck Grassley (R-IA) proposed legislation Tuesday that would end federal funding for "lifestyle" drugs such as sildenafil (Viagra), tadalafil (Cialis), and vardenafil (Levitra) to treat sexual and erectile dysfunction. Coverage would be provided if the drugs are prescribed for a purpose other than sexual performance.
Microsurgical varicocelectomy preferred over conservative treatment
May 25th 2005Men who experience painful recurrent varicoceles after undergoing conservative treatment and failed surgical repair are best served by microsurgical varicocelectomy, according to Canadian researchers.Of 11 men who had failed standard varicocelectomy and experienced pain before and after surgery, 10 experienced a favorable response following microsurgical repair, according to investigators."In my mind, microsurgical varicocelectomy is the gold standard, and non-microsurgical repair is sub-standard," said lead author Armand Zini, MD, associate professor of urology at McGill University, Montreal. "However, few urologists are able to perform this procedure, since they have not been trained properly."
Botulinum may offer option in BPH, but results are equivocal
May 25th 2005Botulinum toxin A (Botox) injections show potential for providing a quick, easy, and safe treatment option for men with lower urinary tract symptoms related to BPH, but two small studies presented yesterday provided equivocal results regarding the efficacy of this investigational approach. U.S. researchers tested their 10-minute, ultrasound-guided technique in a two-part study. In the first part, 10 patients were injected with botulinum, 100 units, to assess safety, International Prostate Symptom Score, flow rates, and bother scores. In the second part, 30 patients received 200 units of botulinum in a sham-controlled, double-blind study, and sequential MRIs were taken pretreatment and at 1 and 3 months post-treatment to measure prostate volume.
Amitriptyline helps, even when patients don't have 'classic' IC
May 24th 2005Amitriptyline has long been used for treating symptoms of interstitial cystitis, but now long-term data confirm its usefulness, even when patients don't fit the strict NIDDK research definition of IC. Key to long-term success is allowing patients to titrate the dose themselves.
Co-prescription of sildenafil with nitrates still occurs
May 24th 2005A study estimating the dispensation rate of interacting medications to an outpatient population found that while only 0.05% of patients received co-prescriptions for medications that could potentially cause adverse effects, about half of these were given were for sildenafil citrate (Viagra) and one of two different nitrates.
Study shows feasibility of genitofemoral nerve grafts during RP
May 24th 2005Genitofemoral (GF) nerve grafting during radical retropubic prostatectomy can be performed safely with a low risk of postoperative morbidity and shows promising efficacy for returning erectile function after surgery involving wide nerve resection, according to the results of a retrospective study undertaken by urologists from Vanderbilt University, Nashville, TN.
Agent for premature ejaculation shows no interactions with PDE-5 inhibitors
May 24th 2005Dapoxetine, the first treatment developed specifically for premature ejaculation, has no significant interaction when taken concurrently with the type-5 phosphodiesterase type-5 inhibitors sildenafil citrate (Viagra) and tadalafil (Cialis), according to results presented here yesterday.
FDA approves generic version of ciprofloxacin for UTIs
May 22nd 2005Depomed, Inc. has received approval from the FDA for a once-daily formulation of ciprofloxacin hydrochloride (Proquin XR) for the treatment of uncomplicated urinary tract infections. It is the first version of ciprofloxacin with nausea and diarrhea listed as "uncommon" adverse events, rather than "common" adverse events, according to the company.
Tissue sealant aids in collecting system repair
May 15th 2005Charleston, SC--A two-component synthetic tissue sealant may serve as a viable alternative to current standard suturing techniques used in collecting system repair, according to researchers from Duke University, Durham, NC. Their research used a swine model to compare two FDA-approved sealants and traditional suturing.
ED agent improves sexual pleasure in both partners
May 15th 2005Istanbul, Turkey--The phosphodiesterase type-5 inhibitor vardenafil (Levitra) significantly improves sexual pleasure and treatment satisfaction in both men with erectile dysfunction and their partners, according to study results presented at the European Association of Urology annual congress here.
Proactive rehab important for PCa patients with ED
May 15th 2005Convincing patients to lose weight and treating them early with standard medical therapies for erectile dysfunction are two ways clinicians can help their patients return to sexual function after radical prostatectomy or radiotherapy for prostate cancer.
Stem cells, botulinum lead advances in incontinence
May 15th 2005The use of non-embryonic stem cells and the growing popularity of botulinum toxin are among key trends to watch for in the management of stress incontinence and overactive bladder, respectively, said Shlomo Raz, MD, director of female urology, urodynamics, and reconstructive surgery at UCLA Medical Center.
Data offer more evidence of botulinum's benefit of OAB
May 15th 2005Istanbul, Turkey--Swiss data add to growing evidence that injecting botulinum toxin A (Botox) into the detrusor muscle is a safe and efficient treatment option in patients suffering from overactive bladder, particularly in cases that prove refractory to other more conventional treatment modalities, like anticholinergic agents and physiotherapy.
BPH patients with inflammation show heightened risk of AUR
May 1st 2005Istanbul, Turkey--Prostate inflammation significantly raises the risk of clinical progression in men with lower urinary tract symptoms and BPH, according to a first-time investigation into the impact of acute and/or chronic inflammation on men with BPH. The most significant impact of acute or chronic inflammation was an increased risk of acute urinary retention, particularly in patients receiving placebo, according to the analysis, based on a subset of patients from the Medical Therapy of Prostatic Symptoms (MTOPS) patient cohort.
PDE-5 inhibitors effective in men on antidepressants
May 1st 2005Montreal--Phosphodiesterase type-5 inhibitors appear to be effective in treating erectile dysfunction in men who are also receiving pharmacologic treatment for depression. A retrospective study presented here at the Canadian Psychiatric Association annual meeting that looked specifically at tadalafil (Cialis) demonstrated that the drug was effective in improving erections and achieving intercourse in this population.
Estrogen receptor modulator prevents PCa in some men
May 1st 2005Orlando, FL--Testosterone's effect on the development and progression of BPH and prostate cancer is well known, but a group of University of Tennessee researchers has been focusing on testosterone's less frequently studied "partner in crime"—estrogen.
Phase II trials of prostate Ca vaccine promising
May 1st 2005Orlando, FL--A genetically modified vaccine has demonstrated immunogenicity and clinical activity in hormone-refractory prostate cancer patients with metastatic disease, researchers reported in a poster presentation at the 2005 Multidisciplinary Prostate Cancer Symposium.